2018 Program ReportApril 30, 2019
In 2017, two Loma Linda University Health (LLUH) physicians travelled to Malawi, a country of 18 million in southeastern Africa. They helped install a new EEG system and launch an epilepsy monitoring unit at Malamulo Hospital, a 250-bed facility in rural southern Malawi (pictured at right).
“One of the major needs in this region is quality care for persons with epilepsy,” says Dr. Travis Losey. “Levetiracetam would be an incredibly helpful addition to the epilepsy treatment options there. The same goes for Queen Elizabeth’s Hospital in Blantyre. It is the teaching hospital for the national medical school. The only neurosurgeon in the nation practices there and he’s partnering with us to develop an epilepsy surgical program. This hospital also do not have access to levetiracetam, and this medication would be a tremendous addition to their treatment program.”
This epilepsy partnership is part of an international mission through the Loma Linda Global Health Institute. ROW is pleased to join this partnership by providing 20 cases of Roweepra® (levetiracetam) to these hospitals. We plan to send follow-up medication grants in keeping with our policy of providing ongoing supplies to our partners because epilepsy is a lifetime struggle. ROW grants are made possible through the generosity of OWP Pharmaceuticals.
On the home front, the ROW Foundation has earned the GuideStar Platinum Seal of Transparency, the highest level of recognition offered by the world’s largest source of information on nonprofit organizations. This puts us in the top 0.5% of profiles in what Time magazine calls, “the nation’s premier nonprofit database.”